Article citationsMore>>

Kootte, R.S., Levin, E., Stroes, E.S.G., Groen, A.K., Nieuwdorp, M., Smits, L.P., et al. (2017) Clinical and Translational Report Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 26, 611-619.

has been cited by the following article:

• TITLE: Fecal Microbiota Transplantation (FMT): Historical Perspectives, Expanding Therapeutic Applications, and Future Prospects in Human Health

  AUTHORS: Parameshwar Jakinala, Harikrishna Naik Lavudi, Badithi Nani Babu, Doni Sri Lakshmi Angadala, Athoti Revanth, Kochera Rachel, Chintakrindi Chandra Sekhar, Anirudh Vivin Sabbi, Ushasree Ravula, Madhumohan Rao Katika

  KEYWORDS: Fecal Microbiota Transplantation, Gut Microbiome, Dysbiosis, Clostridioides difficile, Autoimmune Diseases, Metabolic Disorders

  JOURNAL NAME: Advances in Microbiology, Vol.15 No.8, August 28, 2025

  ABSTRACT: Fecal microbiota transplantation (FMT) has evolved from ancient Chinese medicine to a modern therapeutic intervention, gaining recognition in 1958 for treating pseudomembranous colitis. Today, recurrent Clostridioides difficile infection (rCDI) treatment is highly effective, and it has more than 90% success rate. Beyond rCDI, FMT shows promise in addressing metabolic disorders, autoimmune diseases, skin diseases, glaucoma and autism spectrum disorder, where it may enhance immune checkpoint inhibitor efficacy. However, challenges remain, including the lack of standardized protocols, donor-recipient matching complexities, long-term safety concerns, and ethical issues. Future advancements in personalized FMT, computational tools, and large-scale clinical trials are essential to overcome these limitations and expand its applications. This review highlights FMT’s transformative potential in modern medicine while emphasizing the need for rigorous research, standardized protocols, and innovative strategies to optimize its therapeutic benefits across diverse diseases.